A double‐blind, randomized, placebo‐controlled study to assess the efficacy of Andrographis paniculata standardized extract (ParActin®) on pain reduction in subjects with knee osteoarthritis

Abstract

Andrographis paniculata Wall (Acanthaceae) is becoming more recognized for its anti‐inflammatory and antioxidant properties. A randomized, double‐blind, placebo‐controlled study was conducted to assess the efficacy of an andrographolide‐containing supplement, ParActin® (300 and 600 mg daily), on Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) pain reduction in patients with knee osteoarthritis. Joint stiffness, physical function, changes in the SF‐36 quality of life questionnaire, a fatigue scale, and safety were also evaluated. A total of 103 male and female patients with I‐II osteoarthritis of the knee joint were assessed. Patients treated with 300 or 600 mg/day of ParActin® showed a significant reduction in pain at days 28, 56, and 84 compared with a placebo group. WOMAC stiffness scores, physical function score, and the fatigue score showed a significant improvement in both ParActin®‐treated groups compared with the placebo group. At the end of the study, the quality of life (SF‐36 questionnaire) and Functional Assessment of Chronic Illness Therapy (FACIT) scores showed significant improvements in both ParActin®‐treated groups compared with the placebo group. Overall, it can be concluded that ParActin® in 300 and 600 mg/day dosages were found to be effective and safe in reducing pain in individuals suffering from mild to moderate knee osteoarthritis.

Adult Measures of General Health and Health‐Related Quality of Life

“…The SF‐36 has been extensively used in randomized controlled trials in rheumatic disease settings. Some examples of recent trials that utilized the SF‐36 include the assessments of the efficacy of debridement of unstable chondral lesions versus observation following arthroscopic partial meniscectomy , intra‐articular ozone versus placebo in knee osteoarthritis , the effects of Tai Ji Quan training versus health promotion classes on self‐reported sleep quality in elderly Chinese women with knee osteoarthritis , tofacitinib in combination with conventional disease‐modifying antirheumatic drugs in rheumatoid arthritis , acupuncture versus sham procedure for knee osteoarthritis , and andrographis paniculata extract versus placebo in knee osteoarthritis . The SF‐36 was also used in comparative effectiveness trials, including trials comparing muscle‐stretching exercise and resistance training in fibromyalgia , sensory‐motor training versus resistance training among patients with knee osteoarthritis ; and quadriceps strength training alone versus quadriceps and hip abductor strength training in knee osteoarthritis .…”

Efficacy of andrographolide in not active progressive multiple sclerosis: a prospective exploratory double-blind, parallel-group, randomized, placebo-controlled trial

“…The active and placebo coated tablets were manufactured by Laboratorios Euromed Chile S.A. according to GMP guidelines. In this study, we used a pure andrographolide compound; the dose determination was based on pre-clinical [20] and clinical trials on the use of 150-300 mg/day of AP [9,10]. Andrographolide (99,5% purity) was provided by HPIngredients (Bradenton, FL, USA).…”

“…Andrographolide is a bicyclic diterpenoid lactone isolated from Andrographis paniculata, a medicinal herb from Southeast Asia that has been used for the treatment of common colds, fever, laryngitis, rheumatoid arthritis and osteoarthritis and other infections with no or minimal side effects [8][9][10]. Andrographolide (AP) can be particularly effective in modulating immune responses and has neuroprotective properties [11], which aids in fighting against neurodegeneration induced by inflammatory reactions in neuroglial cultures [12]; it has also been shown to have antioxidant properties in neural tissue [13].…”

Efficacy of andrographolide in not active Progressive Multiple Sclerosis: A prospective exploratory double-blind, parallel-group, randomized, placebo-controlled trial

“…The active and placebo coated tablets were manufactured by Laboratorios Euromed Chile S.A. according to GMP guidelines. In this study, we used pure andrographolide compound; the dose determination was based on pre-clinical [20] and clinical trials on the use of 150-300 mg/day of AP [9,10]. Andrographolide (99,5% purity) was provided by HPIngredients (Bradenton, FL, USA).…”

“…Andrographolide is a bicyclic diterpenoid lactone isolated from Andrographis paniculata, a medicinal herb from Southeast Asia that has been used for the treatment of common colds, fever, laryngitis, rheumatoid arthritis and osteoarthritis and other infections with no or minimal side effects [8][9][10].…”